# US 11,304,919 B2 · Utilization of cilastatin in inhibiting renal disorder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,304,919 B2
- Document ID: US11304919B2
- Status: Granted
- Kind: B2
- Application number: 17/050,883
- Filed: 2019-04-26
- Published: 2021-07-29
- Granted: 2022-04-19
- Earliest claimed: 2018-04-27
- Assignees: Niigata University; Denka Company Limited
- Applicants: Niigata University; Denka Company Limited
- Inventors: Akihiko Saito; Sawako Goto; Yoshiaki Hirayama; Sakari Sekine
- Web page: https://patentgrep.com/patent/US11304919B2

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 49/04: X-ray contrast preparations
- A61P 13/12: of the kidneys
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

One object of the present invention is to provide an inhibitor for renal injuries induced by an iodinated contrast medium. In this invention, cilastatin or a pharmaceutically acceptable salt thereof is used.

## Claims

### Claim 1

A method for inhibiting renal injuries induced by an iodinated contrast medium, the method comprising administering to a subject in need thereof an inhibitor comprising cilastatin or a pharmaceutically acceptable salt thereof as an active component, wherein the iodinated contrast medium is selected from the group consisting of ioversol, iomeprol, iodixanol, and pharmaceutically acceptable salts thereof.

### Claim 2 (depends on 1)

The method for inhibiting renal injuries according to claim 1, wherein the iodinated contrast medium is selected from the group consisting of iomeprol, iodixanol, and pharmaceutically acceptable salts thereof.

### Claim 3 (depends on 1)

The method for inhibiting renal injuries according to claim 1, wherein the inhibitor is in an injectable form.

### Claim 4 (depends on 2)

The method for inhibiting renal injuries according to claim 2, wherein the inhibitor is in an injectable form.

### Claim 5 (depends on 1)

The method for inhibiting renal injuries according to claim 1, wherein the iodinated contrast medium is ioversol or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The method for inhibiting renal injuries according to claim 1, wherein the iodinated contrast medium is iomeprol or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The method for inhibiting renal injuries according to claim 1, wherein the iodinated contrast medium is iodixanol or a pharmaceutically acceptable salt thereof.